@stuart
I'm not sure why the negative reactions on this board on Interstim, but I don't have any experience with it.
However, read this and do a Google search on what is interstim, and if there are no other answers, this might be your least invasive choice.
In 1997, InterStim Therapy, the sacral nerve stimulation device produced by Medtronic, Inc., gained FDA approval as a therapy for individuals with urinary urge incontinence and in 1999, went on to receive FDA approval for frequency-urgency syndrome and non-obstructive urinary retention for patients who fail standard therapies. Currently, more than 600 urologists and urogynecologists worldwide have adopted SNS as a treatment, and more than 8000 devices have been implanted successfully.
InterStim Therapy is a safe, efficacious and reversible therapeutic modality that offers improved voiding function and improved quality of life for appropriately selected individuals. The InterStim electrode delivers a mild electrical signal to the sacral nerve that in turn influences the behavior of the bladder, sphincter and pelvic floor musculature. Placement of the probe is minimally invasive and can be done under local anesthesia, allowing for patient interaction to ensure optimal patient-specific placement. Once the tined probe is positioned in the appropriate sacral foramen via a percutaneous puncture, the tines can be deployed for immediate and secure anchoring into therapeutic position. A neurostimulator is then implanted subcutaneously that can be adjusted by the patient in response to evolving voiding symptoms via a transdermal transducer.
Since its inception, numerous, independent clinical trials have confirmed the efficacy of InterStim Therapy for restoring voiding function in appropriately selected patients. In a series of patients with DI or hyperreflexia, the introduction of InterStim Therapy was associated with a significantly decreased number of pads and voids per day, as well as an increased mean voided volume (p<0.0001).3 Additionally, these patients also reported significant improvement in their quality of life. For patients with demonstrable DI on pre-implantation urodynamics (UDS), the initiation of InterStim sacral nerve neuromodulation resulted in a reduced detrusor activity index on repeat UDS.4 Importantly, the clinical symptoms experience by patients in this series, specifically incontinence episodes, total number of voids and urge events per day, improved in a manner consistent with diminished DI noted on UDS.
Non-obstructive retention has also been successfully treated with sacral nerve stimulation. The return of spontaneous voiding with minimal post-void residual was reported by 77% of women three years following the initial implantation of the InterStim device.2 These findings are consistent with a larger series funded by Medtronic in which 68 patients with urinary retention were implanted with the InterStim system. At 18-month follow-up, 70% had statistically significant improvements in their voided volumes when compared to controls.
The Medtronic device is safe and effective, with a proven track record for individuals appropriately selected. The insertion of the probe and modulator is minimally invasive and well tolerated by most individuals. Importantly this reversible procedure can provide a significant improvement in the quality of life for individuals suffering from a range of urinary dysfunctions.